Today's Most Important Upgrades, Prothena & Biogen Shares Surge on Positive Data

September 28, 2022 3:41 PM EDT
Get Alerts PRTA Hot Sheet
Price: $58.55 --0%

Rating Summary:
    17 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 30 | New: 17
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

BofA Securities upgraded Prothena Corp (NASDAQ: PRTA) to Buy from Neutral and raised its price target to $65.00 from $45.00 following Biogen’s and Eisai’s announced positive topline data from their anti-amyloid beta (Ab) antibody, lecanemab. Shares surged around 80% intra-day today.

Baird upgraded Biogen (NASDAQ: BIIB) to Outperform from Neutral and raised its price target to $340.00 from $224.00. Shares soared more than 29% intra-day today after CLARITY-AD becomes the first clearly positive study for a ABeta-targeting drug in Alzheimer's. According to the analysts, the reported data is pretty much a best-case scenario that not only should lead to approval and reimbursement but could make it challenging for competition (assuming any are successful) to match.

Atlantic Equities upgraded Netflix (NASDAQ: NFLX) to Overweight from Neutral and raised its price target to $283.00 from $211.00, noting it believes the revenue opportunity from the upcoming ad-supported tier isn’t reflected in the price. Shares were trading around 9% higher intra-day.

Evercore ISI upgraded Illumina (NASDAQ: ILMN) to Outperform from In Line and raised its price target to $250.00 from $170.00. Shares were trading 7% higher intra-day.

By Davit Kirakosyan

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Hot List, Upgrades

Related Entities

Robert W Baird